FDA green lights Priovant drug for rare skin disease
RegulatoryapprovedLisrayaPositive
AI Analysis
Summary
The FDA has approved Lisraya, a drug licensed by Roivant from Pfizer, marking the first approval of a Pfizer-licensed asset by the subsidiary and positioning it for treatment of multiple rare inflammatory skin conditions.
Outcome Details
FDA approval for rare skin disease
Importance:8/10
Sentiment:
0.85
FDA approvalrare diseasedermatologyRoivant subsidiaryPfizer licensing
Related Companies
Read the original article
Published by BioPharma Dive on August 28, 2026 1:12 PM